Article

Segment 5 - Value-based Decisions in NSCLC

Dr Peskin discusses programs such as Choosing Wisely and how providers must be mindful of high value, cost-conscious, cost-aware care.

Dr Peskin discusses programs such as Choosing Wisely and how providers must be mindful of “high value, cost-conscious, cost-aware” care. This ensures that only appropriate treatments are administered to patients with cancer.

Dr Sugarbaker suggests to the fellow panelists that the majority of NSCLC patients are not candidates for surgery because they are diagnosed too late for a procedure. Early detection would save a lot of money.

“The issue of imaging and early detection certainly resonates with payers, including myself, and not only economic but ethical considerations,” says Dr Peskin. He adds that while people gravitate toward the terms “targeted” and “precision,” one must verify that those treatments are used by clinicians and oncologists judicially.

Related Videos
Jaime Almandoz, MD, MBA
JC Scott, CEO and president of The Pharmaceutical Care Management Association (PCMA)
Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Adam Colburn, JD, associate vice president for congressional affairs, AMCP
Cathy Eng, MD, FACP, FASCO
Leigh Maria Ramos-Platt, MD
Jorge García, PharmD, MS, MBA, MHA, FACHE, FACCC
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo